Evogene Ltd. Meeting Adjourned Due to Lack of Quorum
Ticker: EVGN · Form: 6-K · Filed: Feb 5, 2025 · CIK: 1574565
Sentiment: neutral
Topics: shareholder-meeting, adjournment, quorum
TL;DR
Evogene's shareholder meeting postponed to Feb 12 due to no-shows, might signal investor apathy.
AI Summary
Evogene Ltd. held a Special General Meeting of Shareholders on February 5, 2025, which was adjourned for one week due to a lack of quorum. The meeting will now reconvene on February 12, 2025, at the same time and place.
Why It Matters
The adjournment of a shareholder meeting can indicate low investor engagement or potential concerns, which could impact stock sentiment.
Risk Assessment
Risk Level: low — The filing is a routine procedural update regarding a shareholder meeting adjournment and does not contain significant financial or operational news.
Key Players & Entities
- Evogene Ltd. (company) — Registrant
- February 5, 2025 (date) — Date of initial shareholder meeting
- February 12, 2025 (date) — Date of reconvened shareholder meeting
FAQ
Why was the Evogene Ltd. Special General Meeting of Shareholders adjourned?
The meeting was adjourned due to a lack of quorum.
When will the Evogene Ltd. Special General Meeting of Shareholders reconvene?
The meeting will reconvene on Wednesday, February 12, 2025.
What is the purpose of the Form 6-K filing by Evogene Ltd.?
The Form 6-K is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
What is the principal executive office address for Evogene Ltd.?
The address is 13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel.
Does Evogene Ltd. file annual reports under Form 20-F or Form 40-F?
Evogene Ltd. files annual reports under cover of Form 20-F.
Filing Stats: 284 words · 1 min read · ~1 pages · Grade level 10.8 · Accepted 2025-02-05 16:00:14
Filing Documents
- zk2532654.htm (6-K) — 12KB
- 0001178913-25-000329.txt ( ) — 13KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission File Number: 001-36187 EVOGENE LTD. (Translation of Registrant's Name into English) 13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F CONTENTS On February 5, 2025, Evogene Ltd. (the " Company ") convened its Special General Meeting of Shareholders (the " Annual Meeting "), however, it was adjourned for one week to the same day, time and place due to lack of quorum. Accordingly, the Company's Special General Meeting will be reconvened on Wednesday, February 12, 2025 at 3:00 p.m. (Israel time), at the executive offices of the Company, 13 Gad Feinstein Street, Park Rehovot, Rehovot, Israel. The content of this Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the registration statements on Form F-3 (File No. 333-277565 ) and on F orm S-8 (SEC File Nos. 333-193788 , 333-201443 , 333-203856 and 333-259215 ) of the Company, and will be a part thereof from the date on which this Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: February 5, 2025 EVOGENE LTD. (Registrant) By: /s/ Yaron Eldad Yaron Eldad Chief Financial Officer